ALB and nephrotic syndrome: The study conducted by Keller et al. is focused on evaluating the pharmacokinetics of furosemide in patients with nephrotic syndrome and it showed the diminished protein binding of furosemide from 98.6% to 97.2% due to low albumin levels in nephrotic patients that were administered 40 mg of furosemide intravenously.